LMNB1/CDKN1A Signaling Regulates the Cell Cycle and Promotes Hepatocellular Carcinoma Progression

Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies in the world. Lamin B1 (LMNB1) is a key component of the nuclear skeleton structure. Recent studies have found that LMNB1 is overexpressed in tumor tissues and is associated with the prognosis of patients. However, the underly...

Full description

Saved in:
Bibliographic Details
Published inCurrent cancer drug targets Vol. 25; no. 6; p. 620
Main Authors Gao, Dute, Guo, Huahu, Liu, Zhaochen, Bao, Liang, Li, Suxin, Wang, Yunchao, Qiu, Jiange, Jiang, Binghua, Dang, Xiaowei
Format Journal Article
LanguageEnglish
Published Netherlands 01.01.2025
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies in the world. Lamin B1 (LMNB1) is a key component of the nuclear skeleton structure. Recent studies have found that LMNB1 is overexpressed in tumor tissues and is associated with the prognosis of patients. However, the underlying mechanism remains unclear in HCC. This study aims to explore the clinical significance and molecular mechanisms of LMNB1 in HCC. The expression level of LMNB1 and its clinical values were analyzed with public databases, and the level of LMNB1 in HCC tissues and adjacent normal tissues was confirmed by qRT-PCR and IHC. Functional assays were conducted to explore the impact of LMNB1 knockdown on cell proliferation both and . Additionally, Genes and Genomes enrichment analysis, recovery analysis, and ChIP assays were employed to investigate its underlying molecular mechanisms. Finally, we carried out an analysis of the relationship between LMNB1 and immune cell infiltration in HCC. LMNB1 was found to be overexpressed in HCC and correlated with the pathological stage and unfavorable prognosis. Functional assays demonstrated that LMNB1 promotes HCC proliferation both and . Further analysis revealed that LMNB1 promotes the progression of HCC by regulating CDKN1A expression. Furthermore, the infiltration of immune cells in HCC tissues suggests a potential correlation between immune infiltration cell markers and the expression of LMNB1. LMNB1 emerged as a promising therapeutic target and prognostic biomarker for HCC, with its expression showing a correlation with several immune infiltration cell markers.
AbstractList Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies in the world. Lamin B1 (LMNB1) is a key component of the nuclear skeleton structure. Recent studies have found that LMNB1 is overexpressed in tumor tissues and is associated with the prognosis of patients. However, the underlying mechanism remains unclear in HCC. This study aims to explore the clinical significance and molecular mechanisms of LMNB1 in HCC. The expression level of LMNB1 and its clinical values were analyzed with public databases, and the level of LMNB1 in HCC tissues and adjacent normal tissues was confirmed by qRT-PCR and IHC. Functional assays were conducted to explore the impact of LMNB1 knockdown on cell proliferation both and . Additionally, Genes and Genomes enrichment analysis, recovery analysis, and ChIP assays were employed to investigate its underlying molecular mechanisms. Finally, we carried out an analysis of the relationship between LMNB1 and immune cell infiltration in HCC. LMNB1 was found to be overexpressed in HCC and correlated with the pathological stage and unfavorable prognosis. Functional assays demonstrated that LMNB1 promotes HCC proliferation both and . Further analysis revealed that LMNB1 promotes the progression of HCC by regulating CDKN1A expression. Furthermore, the infiltration of immune cells in HCC tissues suggests a potential correlation between immune infiltration cell markers and the expression of LMNB1. LMNB1 emerged as a promising therapeutic target and prognostic biomarker for HCC, with its expression showing a correlation with several immune infiltration cell markers.
Author Wang, Yunchao
Dang, Xiaowei
Gao, Dute
Qiu, Jiange
Bao, Liang
Li, Suxin
Guo, Huahu
Liu, Zhaochen
Jiang, Binghua
Author_xml – sequence: 1
  givenname: Dute
  surname: Gao
  fullname: Gao, Dute
  organization: Henan Province Engineering Research Center of Minimally Invasive Diagnosis and Treatment of Hepatobiliary and Pancreatic Diseases, China
– sequence: 2
  givenname: Huahu
  surname: Guo
  fullname: Guo, Huahu
  organization: Henan Province Engineering Research Center of Minimally Invasive Diagnosis and Treatment of Hepatobiliary and Pancreatic Diseases, China
– sequence: 3
  givenname: Zhaochen
  surname: Liu
  fullname: Liu, Zhaochen
  organization: Henan Province Engineering Research Center of Minimally Invasive Diagnosis and Treatment of Hepatobiliary and Pancreatic Diseases, China
– sequence: 4
  givenname: Liang
  surname: Bao
  fullname: Bao, Liang
  organization: Henan Province Engineering Research Center of Minimally Invasive Diagnosis and Treatment of Hepatobiliary and Pancreatic Diseases, China
– sequence: 5
  givenname: Suxin
  surname: Li
  fullname: Li, Suxin
  organization: Henan Province Engineering Research Center of Minimally Invasive Diagnosis and Treatment of Hepatobiliary and Pancreatic Diseases, China
– sequence: 6
  givenname: Yunchao
  surname: Wang
  fullname: Wang, Yunchao
  organization: Department of Clinical Systems Biology Laboratories, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
– sequence: 7
  givenname: Jiange
  surname: Qiu
  fullname: Qiu, Jiange
  organization: Academy of Medical Science, Zhengzhou University, Zhengzhou, China
– sequence: 8
  givenname: Binghua
  surname: Jiang
  fullname: Jiang, Binghua
  organization: Academy of Medical Science, Zhengzhou University, Zhengzhou, China
– sequence: 9
  givenname: Xiaowei
  surname: Dang
  fullname: Dang, Xiaowei
  organization: Henan Province Engineering Research Center of Minimally Invasive Diagnosis and Treatment of Hepatobiliary and Pancreatic Diseases, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38778606$$D View this record in MEDLINE/PubMed
BookMark eNo1j0tLw0AUhQdRtFb_gszCbezcO88sa6xWrFV8rMu8jIFkUpJ00X9viro6cM7Hge-cHKc2RUKugd0gaDFjAFIZxnKFeQ5Mo2ACNdNcoj4iEzCaZ1JqdUrOuNHaKKYmxK6e17cwK-6e1jCn71WZbF2lkr7FclfbIfZ0-I60iHVNi72vI7Up0NeubdrDtoxbO7R-XEe4o4XtfJXaxh6Isot9X7Xpgpx82bqPl385JZ_3i49ima1eHh6L-Spzwogh41KgDdoZD2FUEDw477gfu9wbqTE4lDwCKAXOYeDBOHC5kR6VdYAWp-Tq93e7c00Mm21XNbbbb_5d8QeyF1Ww
CitedBy_id crossref_primary_10_1016_j_jceh_2024_102450
ContentType Journal Article
Copyright Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Copyright_xml – notice: Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.2174/0115680096299107240427073527
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
EISSN 1873-5576
ExternalDocumentID 38778606
Genre Journal Article
GrantInformation_xml – fundername: Key Projects of Institutions of Higher Learning in Henan Province
  grantid: 21A320062
– fundername: National Natural Science Foundation of China
  grantid: 82002560
– fundername: Henan Provincial Science and Natural Science Foundation
  grantid: 232300420232
GroupedDBID CGR
CUY
CVF
ECM
EIF
NPM
ID FETCH-LOGICAL-b484t-3542ad7b8c1d09643dbcb3c2ad9c8572db253e11661bb2d3d8b1b985c26ab12a2
IngestDate Thu May 29 04:59:32 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords CDKN1A
immune infiltration
proliferation
cell cycle
hepatocellular carcinoma
LMNB1
Language English
License Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-b484t-3542ad7b8c1d09643dbcb3c2ad9c8572db253e11661bb2d3d8b1b985c26ab12a2
OpenAccessLink https://www.eurekaselect.com/article/download?doi=10.2174/0115680096299107240427073527
PMID 38778606
ParticipantIDs pubmed_primary_38778606
PublicationCentury 2000
PublicationDate 2025-01-01
PublicationDateYYYYMMDD 2025-01-01
PublicationDate_xml – month: 01
  year: 2025
  text: 2025-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Current cancer drug targets
PublicationTitleAlternate Curr Cancer Drug Targets
PublicationYear 2025
Score 2.4338555
Snippet Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies in the world. Lamin B1 (LMNB1) is a key component of the nuclear skeleton structure....
SourceID pubmed
SourceType Index Database
StartPage 620
SubjectTerms Animals
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Carcinoma, Hepatocellular - genetics
Carcinoma, Hepatocellular - metabolism
Carcinoma, Hepatocellular - pathology
Cell Cycle
Cell Line, Tumor
Cell Proliferation
Cyclin-Dependent Kinase Inhibitor p21 - genetics
Cyclin-Dependent Kinase Inhibitor p21 - metabolism
Disease Progression
Female
Gene Expression Regulation, Neoplastic
Humans
Lamin Type B - genetics
Lamin Type B - metabolism
Liver Neoplasms - genetics
Liver Neoplasms - metabolism
Liver Neoplasms - pathology
Male
Mice
Mice, Nude
Middle Aged
Prognosis
Signal Transduction
Title LMNB1/CDKN1A Signaling Regulates the Cell Cycle and Promotes Hepatocellular Carcinoma Progression
URI https://www.ncbi.nlm.nih.gov/pubmed/38778606
Volume 25
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwELUKSIgLArFv8oFbFSBOnLjHUpYKaIUESNyQ7TgtB1KEkgP8AX_NjN2EsC89RK1dR1HeyyzOLIRsg0qOo2hPewx0sRcapT0RicRjEZNJnIICtkVce_2oexWeXPPrRuO5FrVU5GpHP32aV_IfVGEMcMUs2T8gW50UBuA74AtHQBiOv8L4rNffR0nUOTjt--3mxe0AzWobT2c7zGP5BuxLh_tznUdYXOYGAD4w1wVVlI9w697GonawrVA2upP4j4GLj83qxmtZy0kjUx6ayUMxaLpI8sowP5Z26_WgyCvCHBd2qFvIYVGF_9wW9q3IUGLDroqf-271GVB2UN-OYLy2HWGcCBVx4HHuurqUMtYlN4-5VBeYkU2F-yDI0VGyyQngXgp0s0BrgqMK5kfIYpBK3BUUqGF8f2dBDgQWxLNFDH6YfVdmu5yaIBPgcGAH1fPeNNkeX8vud1cyQ6bL1e-cE2ukXM6R2bF3QduOKvOkYbIFIi1Ndh1JaEUSWpGEAkkokoRaklAgCS1JQt-ShFYkoTWSLJKro8PLTtcbd9bwVCjC3At4iI-iEtpP9rAiW6K0CjSMtbTgMUsU44HxfTDelGJJkAjlq5bgmkVS-UyyJTKZjTKzQmiQqlRKY1J8owsf4YdKGh7Db86V9lfJsrsjN_eufMpNea_WvpxZJzOv1NogUyk8r2YTjL9cbVlgXgDsNVWv
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=LMNB1%2FCDKN1A+Signaling+Regulates+the+Cell+Cycle+and+Promotes+Hepatocellular+Carcinoma+Progression&rft.jtitle=Current+cancer+drug+targets&rft.au=Gao%2C+Dute&rft.au=Guo%2C+Huahu&rft.au=Liu%2C+Zhaochen&rft.au=Bao%2C+Liang&rft.date=2025-01-01&rft.eissn=1873-5576&rft.volume=25&rft.issue=6&rft.spage=620&rft_id=info:doi/10.2174%2F0115680096299107240427073527&rft_id=info%3Apmid%2F38778606&rft_id=info%3Apmid%2F38778606&rft.externalDocID=38778606